Two-Drug combo aims to wipe out rectal cancer before surgery

NCT ID NCT07686796

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial investigates whether adding two targeted drugs—tafolecimab and sintilimab—to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer that has not spread. Participants receive short-course radiation followed by chemotherapy plus immunotherapy, with or without the additional drug. The main goal is to see if the cancer completely disappears before surgery or during a watch-and-wait approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tafolecimab and sintilimab
What this could lead to
If successful, this combination could significantly increase the chance of eliminating all cancer before surgery, potentially allowing some patients to avoid surgery altogether.
What could go wrong
This is an early-phase trial with a relatively small number of participants. Adding these drugs may increase side effects, and the benefit over standard treatment is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAPECITABINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.